Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Other Non-current Assets
Long-term assets not reported separately.
Aktis Oncology, Inc.NASDAQ: AKTS
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets of $3.6M in Q1 FY2026
Q1 FY2026 other non-current assets was $3.6M. Over 3 fiscal years it compounded at +95.8% a year.
Context
- Other non-current assets amounted to 0.6% of total assets at the end of Q1 FY2026.
- Other non-current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 7.33M USD
- Year-over-year change
- +64.4%
- 3-year CAGR
- +95.8%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.33M | +64.4% |
| FY2024 | 2024-12-31 | 4.46M | +263.2% |
| FY2023 | 2023-12-31 | 1.23M | +25.7% |
| FY2022 | 2022-12-31 | 976K | — |
Other Non-current Assets vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 other non-current assets of $3.6M is the 4th highest of the 6 companies compared; the peer median is $7.18M.
- Other non-current assets amounts to 0.6% of total assets for AKTS, versus a peer median of 1.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $18.61M | +8.7% | +32.3% | 1.7% | |
| Mar 2026 | $12.99M | +10.0% | +14.7% | 2.0% | |
| Sep 2026 | $7.18M | +50.7% | +119.8% | 1.4% | |
| Mar 2026 | $3.6M | — | +95.8% | 0.6% | |
| Mar 2026 | $1.38M | -7.7% | +0.2% | 0.6% | |
| Mar 2026 | $1.29M | +67.3% | +43.1% | 0.9% | |
| Peer median (excluding AKTS) | $7.18M | +10.0% | +32.3% | 1.4% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.